Originally published by our sister publication Pharmacy Practice News
By Gina Shaw
503A compounding pharmacies can expect more inspections from their state boards of pharmacy (BOPs) and audits from pharmacy benefit managers (PBMs) due to the rising demand for compounded glucagon-like peptide-1 (GLP-1) medications, cautioned industry experts in a Jan. 29 webinar sponsored by the healthcare law firm Frier Levitt.
“As a result of the significant demand for these products, whether in the branded